Veracyte (NASDAQ:VCYT – Get Free Report) had its target price reduced by research analysts at Stephens from $68.00 to $55.00 in a report issued on Tuesday,Benzinga reports. Stephens’ target price suggests a potential upside of 22.63% from the company’s previous close. According to MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus target price of $54.33. Insider Buying and SellingIn other Veracyte news, CEO Marc Stapley sold 138,051 shares of Veracyte stock in a transaction dated Thursday, June 4th. Veracyte Company Profile(Get Free Report)Veracyte, Inc is a genomic diagnostics company focused on improving diagnostic accuracy and patient care through advanced molecular testing.